Today: September 29, 2016, 5:17 am
  
Business

Toxic Financings Cause The Small Retail Investor To Suffer Most

In an article published by an analyst at Seeking Alpha, investors are learning most small cap companies succumb to toxic financing as a way to stay alive, which can include below-market pricing, warrants and adverse 'ratcheting' provisions.

 

PR-Inside.com: 2014-08-18 07:16:44
Michael Morhamus, who made a name for himself by exposing heavy stock pumping and possible fraud by various publicly traded companies after becoming a regular contributor at the popular investment news portal, this time dives in the institutional investing group known as Ironridge Global IV, Ltd.

That Wall Street fund has entered into more than 50 equity financing transactions in the last three years, but most of those deals may have come at the expense of the small retail investors who were left “holding the bag,” despite best efforts by management teams of to keep their emerging small-cap companies funded and alive.

Morhamus focuses on numerous historic deals listed between Ironridge and various healthcare companies like Genetic Technologies (NASDAQ:GENE), Rosetta Genomics (NASDAQ:ROSG), MEI Pharma Inc(NASDAQ:MEIP), Advaxis, Inc.(NASDAQ:ADXS), Amarantus Bioscience (OTCMKTS:AMBS), Pressure Biosciences (OTCMKTS:PBIO), Uluru Inc. (OTCMKTS:ULUR), PositiveID Corporation (OTCMKTS:PSID), Cord Blood America Inc.(OTCMKTS:CBAI) and IntelliCell BioSciences, Inc. (OTCMKTS:SVFC).

Morhamus points out that here are at many other institutional investment firms which are in the business of "coming to the rescue" of desperate small cap companies who have little choice but to take money however they can, under whatever predatory terms they agree to. He writes that while those firms and their terms may not be fair they are also not illegal.

In recent days, the U.S. Securities and Exchange Commission is rumored to be closing in on some of the more egregious offenders who may be manipulating prices in order to force more debt.

Morhamus’ complete article is available now at: tinyurl.com/seekingalpa

Contact Publicist P. DePalma of UPN
c/o 170-422 Richards Street
Vancouver, British Columbia
V6B 2Z4
Canada

Press Information
UPN
c/o 170-422 Richards Street
Vancouver, British Columbia
V6B 2Z4
Canada

P. DePalma
Publicist

email
tinyurl.com/seekingalpa

Published by
diane walker
01472319008
e-mail
www.in2town.co.uk



# 323 Words
Related Articles
 
More From Business
Apricus Biosciences Closes $3.7 Million Registered Direct [..]
SAN DIEGO, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative [..]
Ashland and Valvoline announce closing of Valvoline [..]
September 28, 2016 COVINGTON and LEXINGTON, Ky. - Ashland Global Holdings Inc. ("Ashland") and Valvoline Inc. ("Valvoline") [..]
Follow the Land Rover Brick Road: New [..]
New Land Rover Discovery shows its unrivalled capability on Guinness World Record-breaking LEGO structure Show-stopping reveal [..]
Medtronic Receives FDA Approval for World's First [..]
The MiniMed® 670G System Features the Company's Most Advanced SmartGuard(TM) Algorithm To-Date DUBLIN - Sept. 28, 2016 [..]
Veidekke ASA: Signed contract to build environmentally [..]
Today Veidekke Entreprenør entered into a contract with Vestfold county municipality to build a new upper secondary school in [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.